Abdulgayoom Mohammed, Mudawi Deena, Lengyel Zsolt, Abo Samra Hayan, Alshurafa Awni, Yassin Mohamed A
Department of Hematology, National Center for Cancer Care and Research, HMC, Doha, Qatar.
Department of PET/CT and Nuclear Medicine, HMC, Doha, Qatar.
Case Rep Oncol. 2023 Jul 12;16(1):511-518. doi: 10.1159/000531230. eCollection 2023 Jan-Dec.
Langerhans cell histiocytosis (LCH) is a rare neoplastic disease characterized by infiltration of histiocytes and dendritic cells into body organs. While treatment is better established in pediatrics, there is still no consensus on therapy in the adult population. Imatinib has shown promising results in some case reports and a small clinical trial. We present here a fifty-nine-year-old patient with LCH in the lung, liver, and bone who responded well to an imatinib dose of 100 mg daily. Her symptoms improved within 3 months of treatment, and subsequent positron emission tomography-computed tomography (PET/CT) showed resolution of 18F-fluorodeoxyglucose (FDG)-avid lesions.
朗格汉斯细胞组织细胞增多症（LCH）是一种罕见的肿瘤性疾病，其特征是组织细胞和树突状细胞浸润身体器官。虽然儿科的治疗方法已较为成熟，但成人患者的治疗仍未达成共识。在一些病例报告和一项小型临床试验中，伊马替尼已显示出有前景的结果。我们在此介绍一位59岁的患者，其肺部、肝脏和骨骼均患有LCH，对每日100毫克的伊马替尼剂量反应良好。治疗3个月内她的症状有所改善，随后的正电子发射断层扫描-计算机断层扫描（PET/CT）显示18F-氟脱氧葡萄糖（FDG）摄取阳性病变消失。
